outbreak
pneumonia
unknown
caus
first
occur
wuhan
china
decemb
recent
assess
world
health
organ
pandem
pneumonia
caus
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
previous
known
diseas
caus
later
design
coronaviru
diseas
march
total
case
report
china
includ
report
death
meanwhil
number
confirm
patient
continu
grow
outsid
china
case
alreadi
report
rel
high
infect
rapid
progress
lung
involv
lack
definit
effect
treatment
make
urgent
develop
effici
measur
manag
base
pathogenesi
although
mani
empir
therapeut
option
introduc
sever
oper
recommend
includ
exist
new
gener
antivir
steroid
tradit
chines
medicin
optim
strategi
sever
remain
unclear
clinic
spectrum
infect
quit
wide
includ
asymptomat
infect
mild
type
upper
respiratori
tract
ill
common
type
pulmonari
infiltr
sever
type
respiratori
distress
critic
ill
patient
need
intub
intens
care
clinic
featur
pneumonia
includ
fever
cough
mani
case
sudden
acceler
respiratori
distress
origin
interstiti
pneumonia
rapidli
progress
critic
condit
reduc
peripher
lymphocyt
count
elev
inflammatori
factor
observ
indic
overwhelm
immun
respons
previou
experi
sar
show
main
pathogenesi
organ
dysfunct
lay
overal
cytokin
dysregul
similarli
point
statu
deterior
start
patient
critic
window
opportun
intervent
report
patient
receiv
highdos
intraven
immunoglobulin
ivig
time
initi
respiratori
distress
satisfactori
clinic
radiograph
recoveri
januari
man
admit
jin
yintan
hospit
wuhan
china
patient
sore
throat
sinc
januari
report
fever
day
admiss
highest
temperatur
given
oseltamivir
azithromycin
local
clinic
empir
cover
communityacquir
respiratori
pathogen
without
improv
januari
came
emerg
depart
jin
yintan
hospit
comput
tomographi
ct
scan
done
show
scatter
interstiti
patch
pleural
thicken
right
side
figur
oropharyng
swab
posit
realtim
revers
transcript
polymeras
chain
reaction
rrtpcr
assay
previous
gener
healthi
deni
exposur
direct
contact
huanan
seafood
market
admiss
afebril
blood
pressur
mmhg
puls
beat
per
minut
respiratori
rate
breath
per
minut
oxygen
satur
breath
ambient
air
lung
clear
auscult
remaind
examin
unremark
laboratori
result
reflect
signific
lymphocytopenia
lymphocyt
count
l
inflammatori
marker
elev
erythrocyt
sediment
rate
esr
mmh
highsensit
creactiv
protein
hscrp
brief
report
ofid
mgl
liver
function
renal
function
within
normal
rang
tabl
detect
antigen
neg
influenza
b
well
subtyp
avian
influenza
viru
patient
diagnos
common
type
support
care
empir
moxifloxacin
given
close
monitor
clinic
statu
intermitt
fever
vital
sign
remain
larg
stabl
januari
cough
short
breath
develop
oxygen
satur
decreas
breath
ambient
air
hscrp
elev
mgl
ct
scan
januari
show
progress
infiltr
bilater
compar
scan
januari
figur
diagnosi
modifi
sever
type
highdos
ivig
start
januari
hospit
day
gd
day
bodi
weight
kg
moxifloxacin
continu
februari
day
ivig
infus
patient
becam
afebril
advers
event
report
next
day
clinic
statu
gradual
improv
supplement
oxygen
discontinu
oxygen
satur
level
return
februari
breath
ambient
air
test
result
februari
show
recov
lymphocyt
count
l
esr
decreas
mmh
hscrp
return
normal
rang
ct
scan
show
partial
resolut
previou
lesion
figur
two
consecut
oropharyng
swab
februari
neg
patient
discharg
februari
man
present
fever
dri
cough
day
admit
januari
jin
yintan
hospit
patient
report
fever
dri
cough
januari
began
feel
short
breath
came
local
hospit
oropharyng
swab
confirm
posit
patient
transfer
jin
yintan
hospit
next
day
histori
hypertens
well
control
valsartan
felodipin
deni
exposur
direct
contact
seafood
market
physic
examin
show
bodi
temperatur
blood
pressur
mmhg
puls
beat
per
minut
respiratori
rate
breath
per
minut
oxygen
satur
breath
ambient
air
laboratori
result
admiss
reflect
mild
thrombocytopenia
l
moder
elev
inflamm
marker
includ
esr
mmh
hscrp
mgl
level
creatin
kinas
elev
ul
myoglobin
mildli
increas
ngml
tabl
igm
test
respiratori
pathogen
neg
influenza
b
parainfluenza
respiratori
syncyti
viru
rsv
adenoviru
mump
viru
microviru
ct
scan
januari
indic
bilater
infiltr
opac
promin
right
side
figur
patient
diagnos
sever
type
ivig
administ
immedi
dose
gd
day
bodi
weight
kg
patient
becam
afebril
second
day
ivig
treatment
gradual
improv
breath
difficulti
ct
scan
repeat
februari
show
promin
absorpt
compar
scan
januari
figur
nasal
pcr
test
turn
neg
februari
discharg
februari
woman
admit
jin
yintan
hospit
januari
report
malais
lowgrad
fever
maxim
mild
cough
sinc
januari
ct
scan
local
hospit
show
mild
groundglass
opac
nasopharyng
swab
posit
oral
lopinavirritonavir
prescrib
close
monitor
patient
develop
highdegre
fever
around
januari
obviou
short
breath
got
admit
januari
previous
gener
healthi
report
close
contact
colleagu
diagnos
day
admiss
afebril
blood
pressur
mmhg
puls
beat
per
minut
respiratori
rate
breath
per
minut
oxygen
satur
breath
ambient
air
lung
clear
auscult
laboratori
studi
reveal
mild
lymphocytopenia
lymphocyt
count
l
slightli
elev
hscrp
mgl
tabl
igm
test
respiratori
pathogen
neg
influenza
b
parainfluenza
rsv
adenoviru
mump
viru
microviru
chest
ct
scan
januari
show
multipl
groundglass
opac
infiltr
bilater
advanc
scan
januari
figur
lopinavirritonavir
continu
complet
cours
patient
temperatur
januari
develop
short
breath
oxygen
satur
decreas
breath
ambient
air
promin
deterior
also
notic
chest
ct
accompani
reduct
lymphocyt
count
l
elev
hscrp
mgl
figur
clinic
diagnosi
grade
modifi
common
sever
type
ivig
administ
begin
januari
gd
day
bodi
weight
kg
meanwhil
methylprednisolon
mgd
given
day
fever
subsid
first
day
enhanc
treatment
symptom
improv
significantli
day
later
oxygen
satur
return
breath
ambient
air
neg
pcr
test
confirm
februari
chest
ct
scan
reveal
radiograph
resolut
figur
discharg
februari
valu
patient
normal
brief
report
ofid
although
confirm
case
rapidli
accumul
past
month
understand
clinic
spectrum
pathophysiolog
chang
infect
still
remain
limit
nevertheless
definit
treatment
identifi
make
clinic
manag
extrem
difficult
report
case
seri
patient
success
treat
highdos
ivig
earli
stage
clinic
deterior
base
observ
high
dose
ivig
administ
appropri
point
could
success
block
progress
diseas
cascad
improv
outcom
natur
histori
infect
resembl
previous
known
coronavirus
date
notic
quit
wide
clinic
spectrum
infect
includ
asymptomat
infect
mild
upper
respiratori
tract
ill
pulmonari
infiltr
larg
proport
report
symptomat
case
includ
patient
mani
other
follow
similar
track
progress
infect
often
start
mild
moder
unspecif
symptom
includ
limit
lowgrad
fever
sore
throat
cough
fatigu
malais
similar
symptom
common
cold
initi
symptom
would
abat
persist
around
day
highgrad
fever
develop
respiratori
distress
becam
quit
promin
patient
would
also
gastrointestin
symptom
period
howev
look
ct
seri
shown
quit
typic
patient
would
strong
impress
lesion
start
peripheri
especi
subpleur
region
acut
respiratori
distress
syndrom
ard
develop
featur
indic
hematogen
lymphat
distribut
spread
pathogen
factor
rather
direct
inspir
base
observ
deduc
symptomat
mainli
consist
phase
includ
start
phase
span
acquisit
viru
subsequ
viremia
mani
patient
acceler
phase
virusinduc
secondari
damag
target
organ
tissu
occur
includ
lung
heart
gastrointestin
tract
even
overal
inflammatori
storm
third
phase
final
recoveri
phase
demonstr
clinic
featur
also
laboratori
dynam
includ
progress
lymphocytopenia
elev
inflamm
marker
time
acceler
therefor
strategi
also
specifi
accord
cours
infect
best
time
antivir
use
may
lie
phase
acceler
clinic
deterior
begin
first
day
deterior
may
present
critic
point
potent
suppress
inflammatori
cascad
could
save
patient
fatal
immunemedi
injuri
shown
moreov
experi
patient
acceler
diseas
could
stop
seem
work
well
even
effect
antivir
drug
given
result
highdos
ivig
g
per
kg
weight
per
day
five
day
use
patient
potent
safe
immun
modul
dose
ivig
determin
base
wellestablish
practic
immun
modul
therapi
diseas
includ
neuromuscular
disord
autoimmun
thrombocytopen
purpura
etc
consider
potenti
cardiac
renal
impair
sever
patient
none
patient
report
advers
event
patient
clinic
improv
shortli
administr
temperatur
back
normal
day
breath
difficulti
allevi
day
confound
factor
exist
includ
use
differ
antivir
patient
variou
time
point
short
cours
steroid
patient
moreov
patient
valsartan
angiotensin
receptor
blocker
use
treat
hypertens
angiotensinconvert
enzym
identifi
major
receptorbind
domain
hypothesi
higher
express
chronic
medic
may
protect
patient
acut
lung
injuri
rather
put
higher
risk
though
current
remain
unproven
nevertheless
timelin
pattern
diseas
cours
patient
probabl
highdos
ivig
play
lead
role
recoveri
ivig
blood
product
contain
polyclon
immunoglobulin
g
isol
pool
healthi
donor
use
year
complex
prepar
contain
larg
number
bioactiv
moieti
entireti
effect
yet
fulli
understood
ivig
higher
dose
choic
immunomodulatori
therapi
autoimmun
inflammatori
diseas
prophylaxi
treatment
sever
infect
especi
immunocompromis
patient
sever
theori
propos
explain
potenti
immunomodulatori
mechan
includ
fcmediat
fabmedi
approach
previou
studi
sar
middl
east
respiratori
syndrom
mer
ivig
therapi
exhibit
variou
clinic
benefit
good
toler
consid
efficaci
improv
passiv
immun
modul
immun
inflamm
overal
safeti
profil
highdos
ivig
could
consid
promis
option
earli
stage
clinic
deterior
patent
report
limit
small
number
patient
includ
evid
need
confirm
conclus
howev
report
provid
import
therapeut
clue
current
situat
rapid
diseas
spread
time
ivig
administr
critic
practic
patient
might
receiv
much
benefit
system
damag
alreadi
taken
place
current
random
control
trial
evalu
effici
highdos
ivig
therapi
sever
initi
nct
provid
evid
ivig
use
treat
patient
